A RARE CASE OF MULTIPLE-PRIMARY CANCER IN A WOMAN WITH BRCA 1 GENE MUTATION: BRCA-ASSOCIATED OVARIAN CANCER AND LUNG CARCINOID TUMOR
https://doi.org/10.21294/1814-4861-2018-17-1-99-103
Abstract
Inherited mutations in the BRCA1 and BRCA2 genes more often provoke the development of metachronous tumors compared to the general population. Women who carry inherited BRCA1 mutations have an increased risk of developing not only breast and ovarian cancers, but they have also increased risks of developing other types of cancers, such as cervical cancer, endometrial (uterine), ovarian, pancreatic, prostate, and salivary gland cancers. Common views on the pathogenesis of hereditary cancers imply that the development of the tumor is always preceded by the loss of the remaining (normal) allele of the involved gene. Nevertheless, there is reliable information that some BRCA1-associated ovarian cancers demonstrate retention of the second BRCA1copy. We report a rare case of the development of neuroendocrine cell carcinoma- metachronous ovarian cancer and lung carcinoid tumor in the patient with the BRCA1 gene mutation. In addition, the tumor demonstrated loss of heterozygosity at the BRCA1 locus (loss of the wild-type allele).
Supporting agencies: Russian Science Foundation, grant 14-25-00111
About the Authors
A. О. Ivantsov
N.N. Petrov National Medical Research Center of Oncology
Russian Federation
Russian Federation
Alexandr O. Ivantsov - MD, PhD, Senior Researcher, Laboratory of Tumor Morphology, SPIN-code: 8347-0332.
68, Leningradskaya Str., Pesochnyi village, 197758-Saint-Petersburg
M. A. Kleshchov
N.N. Petrov National Medical Research Center of Oncology
Russian Federation
Russian Federation
Maksim A. Kleshchev - Researcher, Laboratory of Tumor Morphology, SPIN-code: 3500-5468.
68, Leningradskaya Str., Pesochnyi village, 197758-Saint-Petersburg
Т. V. Gorodnova
N.N. Petrov National Medical Research Center of Oncology
Russian Federation
Russian Federation
Tatiana V. Gorodnova - MD, PhD, Researcher, Department of Gynecological Oncology, SPIN-code: 2661-9106.
68, Leningradskaya Str., Pesochnyi village, 197758-Saint-Petersburg
A. P. Sokolenko
N.N. Petrov National Medical Research Center of Oncology
Russian Federation
Russian Federation
Anna P. Sokolenko - MD, PhD, Researcher, Laboratory of Molecular Oncology.
68, Leningradskaya Str., Pesochnyi village, 197758-Saint-Petersburg
Kh. B. Kotiv
N.N. Petrov National Medical Research Center of Oncology
Russian Federation
Russian Federation
Khristina B. Kotiv - MD, Postgraduare, Department of Gynecological Oncology, SPIN-code: 3049-8250.
68, Leningradskaya Str., Pesochnyi village, 197758-Saint-Petersburg
I. D. Amelina
N.N. Petrov National Medical Research Center of Oncology
Russian Federation
Russian Federation
Inna D. Amelina - MD, Physician, Imaging Diagnostic Department.
68, Leningradskaya Str., Pesochnyi village, 197758-Saint-Petersburg
А. Е. Mikhnin
N.N. Petrov National Medical Research Center of Oncology
Russian Federation
Russian Federation
Alexandr E. Mikhnin - MD, DSc, Leading Researcher, Department of Thoracic Surgery.
68, Leningradskaya Str., Pesochnyi village, 197758-Saint-Petersburg
А. F. Urmancheeva
N.N. Petrov National Medical Research Center of Oncology
Russian Federation
Russian Federation
Adelia F. Urmancheeva - MD, DSc, Professor, Leading Researcher, Department of Gynecological Oncology, SPIN-code: 4169-6011.
68, Leningradskaya Str., Pesochnyi village, 197758-Saint-Petersburg
I. V. Berlev
N.N. Petrov National Medical Research Center of Oncology
Russian Federation
Russian Federation
Igor V. Berlev - MD, DSc, Professor, Head of the Department of Gynecological Oncology.
68, Leningradskaya Str., Pesochnyi village, 197758-Saint-Petersburg
Е. N. Imyanitov
N.N. Petrov National Medical Research Center of Oncology
Russian Federation
Russian Federation
Evgeny N. Imyanitov - MD, DSc, Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Laboratory of Molecular Oncology, SPIN-code: 1909-7323.
68, Leningradskaya Str., Pesochnyi village, 197758-Saint-PetersburgReferences
1. Brose M.S., Rebbeck T.R., Calzone K.A., Stopfer J.E., Nathanson K.L., Weber B.L. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002 Sep 18; 94 (18): 1365–72.
2. Kadouri L., Hubert A., Rotenberg Y., Hamburger T., Sagi M., Nechushtan C., Abeliovich D., Peretz T. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet. 2007 Jul; 44 (7): 467–71. doi: 10.1136/jmg.2006.048173.
3. Thompson D., Easton D., Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002; 18 (94): 1358–65.
4. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., Pasini B. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 5 (72): 1117–1130.
5. Ferrone C.R., Levine D.A., Tang L.H., Allen P.J., Jarnagin W., Brennan M.F., Offit K., Robson M.E. BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma. J Clin Oncol. 2009 Jan 20; 27 (3): 433–8. doi: 10.1200/JCO.2008.18.5546.
6. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed. 2005 Jun 29; 7 (2): 60.
7. Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q., De DieSmulders C., Persky N., Grompe M., Joenje H., Pals G., Ikeda H., Fox E.A., D’Andrea A.D. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002 Jul 26; 297 (5581): 606–9. doi: 10.1126/science.1073834.
8. O’Donovan P., Livingston D. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010 Jun; 31 (6): 961–7. doi: 10.1093/carcin/bgq069.
9. Böhm S., Faruqi A., Said I., Lockley M., Brockbank E., Jeyarajah A., Fitzpatrick A., Ennis D., Dowe T., Santos J.L., Cook L.S., Tinker A.V., Le N.D., Gilks C.B., Singh N. Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol. 2015 Aug 1; 33 (22): 2457–63. doi: 10.1200/JCO.2014.60.5212.
10. Said I., Böhm S., Beasley J., Ellery P., Faruqi A.Z., Ganesan R., Hirschowitz L., Jeetle S., Leen S.L., McCluggage W.G., McDermott J., Merard R., Millner T.O., Trevisan G., Vella J., Gilks C.B., Singh N. The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma. Int J Gynecol Pathol. 2017 Mar; 36 (2): 172–79. doi: 10.1097/PGP.0000000000000307.
Review
For citations:
Ivantsov A.О., Kleshchov M.A., Gorodnova Т.V., Sokolenko A.P., Kotiv Kh.B., Amelina I.D., Mikhnin А.Е., Urmancheeva А.F., Berlev I.V., Imyanitov Е.N. A RARE CASE OF MULTIPLE-PRIMARY CANCER IN A WOMAN WITH BRCA 1 GENE MUTATION: BRCA-ASSOCIATED OVARIAN CANCER AND LUNG CARCINOID TUMOR. Siberian journal of oncology. 2018;17(1):99-103. (In Russ.) https://doi.org/10.21294/1814-4861-2018-17-1-99-103
Views:
1275
Email this article 
